GSK3B and myocardial infarction: Inhibition of GSK3β by the allosteric inhibitor NP12 led to better systolic (enhancement of EF and FS) and diastolic (as attested by clear effects on deceleration time) function compared to controls, 7 and 14 days post-MI in a mouse I/R model [53].